Kenvue

KVUE

Market cap $31.2B

Don't just look at share price appreciation. Why? It doesn't tell the whole story.

Kenvue offers stable financials, a robust 5% dividend yield, and the stock trades at a significant discount to peers and historical averages. KVUE's recent decline, driven by Tylenol-related headlines, presents an attractive entry point for income and value investors. While some brand deterioration and competition exist, KVUE's core products and cash flows remain strong, supporting ongoing dividend payouts.

SUMMIT, N.J. & OAKLAND, Calif.--(BUSINESS WIRE)--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec®, Neutrogena®, and Listerine®, to accelerate end-to-end R&D efforts across the company's global portfolio of brands. The partnership enables Kenvue to streamline, digitalize, and accelerate the end-to-end product lifecycle by leveraging Albert Invent's foundational AI models. The companies bega.

Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved.

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deliver 23.93% to 38.57% net gains by October 2026, based on analyst targets. Stocks like CAG, VZ, DOC, BMY, KVUE, CPB, UDR, VTRS, KIM, TFC, KEY, HPQ, T, and RF meet the ideal of dividends from $1K invested exceeding share price.

In today's uncertain economic environment, investing in robust dividend stocks can be a great hedge. Companies that can consistently issue growing payouts tend to have strong underlying businesses capable of surviving economic conditions that keep changing.

This October's Dividend Kings list features 56 stocks, with Kenvue and United Bankshares meeting the ideal "fair price" yield criteria. Analysts project the top-ten Dividend Kings could deliver 19.2% to 41.5% net gains by October 2026, with KVUE offering the highest upside. Only two of the top-ten Kings, KVUE and UBSI, are considered "safer" with sufficient free cash flow to cover their dividends at current prices.

Republicans and Democrats are divided along party lines as to whether they believe the U.S. government's claim that women who take Tylenol during pregnancy are raising the risk of autism in their unborn children, a new poll from KFF found.

It's fun to follow stocks that soared recently, and it can be sobering to see which ones have plunged -- especially if you're a shareholder. So here's a look at the worst-performing stocks in the S&P 500 index of 500 of America's biggest companies -- in September.

Investors are wondering if the recent weakness in Kenvue (KVUE 3.28%) stock is a buying opportunity for long-term buyers.